Cognetivity Neurosciences Ltd
CNSX:CGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cognetivity Neurosciences Ltd
Net Income (Common)
Cognetivity Neurosciences Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cognetivity Neurosciences Ltd
CNSX:CGN
|
Net Income (Common)
-CA$7.4m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Oncolytics Biotech Inc
TSX:ONC
|
Net Income (Common)
-CA$30.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-7%
|
|
|
R
|
Revive Therapeutics Ltd
CNSX:RVV
|
Net Income (Common)
-CA$10.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-14%
|
|
|
Avicanna Inc
TSX:AVCN
|
Net Income (Common)
-CA$2.8m
|
CAGR 3-Years
42%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cannabix Technologies Inc
CNSX:BLO
|
Net Income (Common)
-CA$4.7m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-10%
|
|
|
Microbix Biosystems Inc
TSX:MBX
|
Net Income (Common)
-CA$4.3m
|
CAGR 3-Years
-122%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
Cognetivity Neurosciences Ltd
Glance View
Cognetivity Neurosciences Ltd. operates as a technology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-03-19. The firm is engaged in developing a cognitive testing platform, the integrated cognitive assessment (ICA), for use in medical and commercial environments for allowing early diagnosis of dementia. The Company’s ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from early detection of cognitive impairment in dementia and multiple sclerosis (MS), to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The firm serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe.
See Also
What is Cognetivity Neurosciences Ltd's Net Income (Common)?
Net Income (Common)
-7.4m
CAD
Based on the financial report for Jan 31, 2023, Cognetivity Neurosciences Ltd's Net Income (Common) amounts to -7.4m CAD.
What is Cognetivity Neurosciences Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-38%
Over the last year, the Net Income (Common) growth was 43%. The average annual Net Income (Common) growth rates for Cognetivity Neurosciences Ltd have been -41% over the past three years , -38% over the past five years .
